arrow_back Back to App

Faster Access to Affordable Medicines: Stopping Competition Blockades

This bill aims to speed up the market entry of cheaper generic and biosimilar drugs. It prevents pharmaceutical companies from blocking competition by filing baseless petitions, which should lower drug prices and increase their availability for citizens.
Key points
Facilitates access to more affordable generic and biosimilar drugs, potentially lowering healthcare costs for citizens.
Imposes financial penalties on companies that intentionally delay the approval of cheaper drug alternatives.
Strengthens the Federal Trade Commission's role in combating unfair market practices in the pharmaceutical industry.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2883
Sponsor: Rep. Jeffries, Hakeem S. [D-NY-8]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Stop Stalling Access to Affordable Medications

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2883.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Facilitates access to more affordable generic and biosimilar drugs, potentially lowering healthcare costs for citizens.
  • Imposes financial penalties on companies that intentionally delay the approval of cheaper drug alternatives.
  • Strengthens the Federal Trade Commission's role in combating unfair market practices in the pharmaceutical industry.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Jeffries, Hakeem S. [D-NY-8].

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 31 - 9.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Courts and Law Economy